New hope for toddlers with sickle cell: drug may stop painful attacks

NCT ID NCT06923111

Recruiting now Prevention Sponsor: Nova Laboratories Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a liquid medicine called Xromi (hydroxycarbamide) can safely prevent painful complications of sickle cell disease in children aged 9 months to 2 years. About 180 children will take part, with some receiving Xromi and a comparison group of similar children who did not get the drug. Researchers will track side effects and how well the medicine works over 2 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inherited hemoglobinopathy sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE

Contacts and locations

Locations

Basildon University Hospital
RECRUITING

Basildon, United Kingdom
Evelina London Children's Hospital
RECRUITING

London, United Kingdom
John Radcliffe Hospital
RECRUITING

Oxford, United Kingdom
Kings College Hospital
RECRUITING

London, United Kingdom
Noah's Ark Children's Hospital for Wales
RECRUITING

Cardiff, United Kingdom
North Middlesex University Hospital
RECRUITING

London, United Kingdom
Royal Manchester Children's Hospital
RECRUITING

Manchester, United Kingdom
The Royal London Hospital
RECRUITING

London, United Kingdom
University College London Hospital
RECRUITING

London, United Kingdom
Universitätsklinikum Hamburg-Eppendorf
RECRUITING

Hamburg, Germany
Universitätsklinikum Heidelberg
RECRUITING

Heidelberg, Germany
Whittington Hospital
RECRUITING

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.